Enovis Corporation (NYSE:ENOV - Get Free Report) insider Oliver Engert purchased 1,000 shares of the business's stock in a transaction dated Friday, March 13th. The shares were purchased at an average cost of $23.74 per share, for a total transaction of $23,740.00. Following the purchase, the insider directly owned 48,640 shares of the company's stock, valued at $1,154,713.60. This trade represents a 2.10% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
Oliver Engert also recently made the following trade(s):
- On Monday, March 9th, Oliver Engert acquired 1,000 shares of Enovis stock. The stock was purchased at an average price of $23.39 per share, with a total value of $23,390.00.
- On Friday, March 6th, Oliver Engert acquired 750 shares of Enovis stock. The shares were purchased at an average cost of $24.41 per share, with a total value of $18,307.50.
- On Wednesday, March 4th, Oliver Engert bought 250 shares of Enovis stock. The shares were acquired at an average price of $25.10 per share, for a total transaction of $6,275.00.
- On Tuesday, March 3rd, Oliver Engert bought 1,000 shares of Enovis stock. The stock was acquired at an average cost of $24.77 per share, for a total transaction of $24,770.00.
- On Friday, February 27th, Oliver Engert purchased 1,000 shares of Enovis stock. The shares were acquired at an average price of $25.50 per share, with a total value of $25,500.00.
Enovis Trading Up 1.0%
ENOV opened at $23.23 on Tuesday. The company has a debt-to-equity ratio of 0.85, a current ratio of 2.02 and a quick ratio of 1.04. The company has a market cap of $1.33 billion, a price-to-earnings ratio of -1.12 and a beta of 1.46. The firm has a 50 day simple moving average of $23.73 and a 200 day simple moving average of $27.72. Enovis Corporation has a fifty-two week low of $21.00 and a fifty-two week high of $40.69.
Enovis (NYSE:ENOV - Get Free Report) last announced its quarterly earnings data on Thursday, February 26th. The company reported $0.95 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.81 by $0.14. Enovis had a negative net margin of 52.69% and a positive return on equity of 8.74%. The firm had revenue of $575.76 million for the quarter, compared to analysts' expectations of $584.30 million. During the same period last year, the firm earned $0.98 earnings per share. The business's revenue for the quarter was up 2.6% on a year-over-year basis. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. On average, sell-side analysts anticipate that Enovis Corporation will post 2.79 earnings per share for the current year.
Institutional Investors Weigh In On Enovis
Several large investors have recently made changes to their positions in ENOV. River Road Asset Management LLC raised its holdings in shares of Enovis by 3.2% during the fourth quarter. River Road Asset Management LLC now owns 1,487,277 shares of the company's stock worth $39,621,000 after acquiring an additional 46,289 shares during the period. Corient Private Wealth LLC boosted its stake in Enovis by 540.7% in the 4th quarter. Corient Private Wealth LLC now owns 55,180 shares of the company's stock worth $1,470,000 after purchasing an additional 46,568 shares during the period. Front Street Capital Management Inc. boosted its stake in Enovis by 75.8% in the 4th quarter. Front Street Capital Management Inc. now owns 361,932 shares of the company's stock worth $9,642,000 after purchasing an additional 156,069 shares during the period. XTX Topco Ltd bought a new position in Enovis during the 4th quarter worth about $561,000. Finally, Susquehanna Portfolio Strategies LLC raised its stake in shares of Enovis by 249.9% in the 4th quarter. Susquehanna Portfolio Strategies LLC now owns 140,997 shares of the company's stock valued at $3,756,000 after purchasing an additional 100,704 shares during the period. Institutional investors own 98.45% of the company's stock.
Wall Street Analyst Weigh In
Several research analysts have recently issued reports on ENOV shares. Zacks Research upgraded Enovis from a "hold" rating to a "strong-buy" rating in a research report on Wednesday, March 4th. UBS Group reissued a "buy" rating and issued a $50.00 target price on shares of Enovis in a research note on Monday, January 5th. Evercore restated an "outperform" rating on shares of Enovis in a report on Monday, January 12th. Canaccord Genuity Group decreased their target price on Enovis from $58.00 to $50.00 and set a "buy" rating for the company in a research report on Wednesday, December 17th. Finally, BTIG Research upped their price target on Enovis from $41.00 to $43.00 and gave the company a "buy" rating in a research note on Thursday, February 26th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $47.43.
Get Our Latest Report on ENOV
About Enovis
(
Get Free Report)
Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.
The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
